News | EP Lab | February 01, 2017

Scientists Keep Human Hearts Alive in Lab to Track Abnormal Beats

Researchers ‘reanimate’ parts of human hearts to find elusive sources of arrhythmia

Ohio State, Wexner Medical Center, keeping human hearts alive, track abnormal beats, reanimate, Vadim Fedorov

Part of a donated human heart is reanimated and recorded with four high-definition optic cameras in a laboratory at The Ohio State University Wexner Medical Center. Researchers keep the heart tissue alive to look for the causes of irregular heartbeats in cases of persistent atrial fibrillation. Image courtesy of The Ohio State University Wexner Medical Center.


February 1, 2017 — Researchers have developed a technique that allows them to revive parts of human hearts in the laboratory for up to 12 hours while they search for hidden sources of irregular heartbeats.

“It’s amazing. You can see the heart start beating again, which gives us an opportunity to study it with high-speed, high-tech equipment,” said Vadim Fedorov, Ph.D., a biologist who developed the technique at The Ohio State University Wexner Medical Center. “This allows us to see the heart in 3-D and search for sources of irregular beats that we’ve never been able to find.”

The hearts are donated by transplant patients who are receiving new hearts. Scientists take the top portions, known as the atria, and place them in a dish surrounded by four high-speed optical cameras. They then reanimate the tissue and inject it with a special dye that detects electrical signals.

“Normal imaging techniques give us one to two hundred recordings of the heart,” said Fedorov. “These cameras are able to give us 40,000 recordings, all in 3-D.”

The images allow experts to more clearly map the heart and find new areas in which to perform ablations, a procedure during which tiny cuts or burns are made to form scar tissue on the heart. The scar tissue can help disrupt the electrical circuitry of the heart and stop irregular beats.

Knowing exactly where to ablate the small areas of the heart can be challenging, especially in patients who have persistent atrial fibrillation. Their hearts beat erratically 24 hours per day, which can lead to stroke or heart failure.

“This will allow us to map the heart more completely and eventually may help us personalize our procedures according to each patient’s individual needs,” said John Hummel, M.D., director of clinical electrophysiology research at Ohio State Wexner Medical Center. “While it’s still in the early stages, the work Dr. Fedorov is doing with human heart tissue is the kind of thing that will make pivotal changes in our ability to manage patients’ diseases in the coming years.”

For more information: www.wexnermedical.osu.edu


Related Content

News | Atrial Fibrillation

Sept. 11, 2024 — In the first national estimate in two decades, researchers at the University of California-San ...

Home September 11, 2024
Home
News | Atrial Fibrillation

July 24, 2024 — Volta Medical, a health technology company developing artificial intelligence (AI) solutions to assist ...

Home July 24, 2024
Home
News | Atrial Fibrillation

July 8, 2024 — Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF) ...

Home July 08, 2024
Home
News | Atrial Fibrillation

June 12, 2024 — A team of Ochsner Health cardiologists recently published an article in the Journal of the American ...

Home June 12, 2024
Home
News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
Subscribe Now